Home LiteratureArticle Details
PMID: 19568282 Published · ppublish English Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't Review

Cell cycle kinases as therapeutic targets for cancer.

Nature reviews. Drug discovery ·Vol. 8 ·No. 7 ·2009-07-00 ·Pages 547-66

Lapenna S, Giordano A

Abstract

Several families of protein kinases orchestrate the complex events that drive the cell cycle, and their activity is frequently deregulated in hyperproliferative cancer cells. Although several molecules that inhibit cell cycle kinases have been developed and clinically screened as potential anticancer agents, none of these has been approved for commercial use and an effective strategy to specifically control malignant cell proliferation has yet to be established. However, recent genetic and biochemical studies have provided information about the requirement for certain cell cycle kinases by specific tumours and specialized tissue types. Here, we discuss the potential and limitations of established cell cycle kinases as targets in anticancer drug discovery as well as novel strategies for the design of new agents.

MeSH Terms
Animals Aurora Kinases Cell Cycle Cell Cycle Proteins/antagonists & inhibitors,chemistry Cyclin-Dependent Kinases/antagonists & inhibitors DNA Damage Humans Neoplasms/drug therapy Protein Kinase Inhibitors/therapeutic use Protein Serine-Threonine Kinases/antagonists & inhibitors,chemistry Proto-Oncogene Proteins/antagonists & inhibitors,chemistry Retinoblastoma-Like Protein p130/physiology Staurosporine/analogs & derivatives,therapeutic use
Chemicals
Cell Cycle Proteins Protein Kinase Inhibitors Proto-Oncogene Proteins Retinoblastoma-Like Protein p130 7-hydroxystaurosporine Aurora Kinases Protein Serine-Threonine Kinases polo-like kinase 1 Cyclin-Dependent Kinases Staurosporine
Authors & Affiliations
2 authors, click to expand affiliations / ORCID
Lapenna Silvia
Oncology Research Centre of Mercogliano, Mercogliano, Avellino, Italy. [email protected]
Giordano Antonio
References (170)
170 references, click to expand
  1. A requirement for cyclin-dependent kinase 6 in thymocyte development and tumorigenesis.
    Cancer Res. 2009 Feb 1;69(3):810-8 PMID: 19155308
  2. A phase I dose escalation study of the pharmacokinetics and tolerability of ZK 304709, an oral multi-targeted growth inhibitor (MTGI), in patients with advanced solid tumours.
    Cancer Chemother Pharmacol. 2009 Jul;64(2):425-9 PMID: 19280191
  3. N-(cycloalkylamino)acyl-2-aminothiazole inhibitors of cyclin-dependent kinase 2. N-[5-[[[5-(1,1-dimethylethyl)-2-oxazolyl]methyl]thio]-2-thiazolyl]-4- piperidinecarboxamide (BMS-387032), a highly efficacious and selective antitumor agent.
    J Med Chem. 2004 Mar 25;47(7):1719-28 PMID: 15027863
  4. Use of the novel Plk1 inhibitor ZK-thiazolidinone to elucidate functions of Plk1 in early and late stages of mitosis.
    Mol Biol Cell. 2007 Oct;18(10):4024-36 PMID: 17671160
  5. In vivo antitumor activity of a novel sulfonamide, HMN-214, against human tumor xenografts in mice and the spectrum of cytotoxicity of its active metabolite, HMN-176.
    Invest New Drugs. 2003 Nov;21(4):387-99 PMID: 14586206
  6. Requirements for Cdk7 in the assembly of Cdk1/cyclin B and activation of Cdk2 revealed by chemical genetics in human cells.
    Mol Cell. 2007 Mar 23;25(6):839-50 PMID: 17386261
  7. Preclinical activity of P276-00, a novel small-molecule cyclin-dependent kinase inhibitor in the therapy of multiple myeloma.
    Leukemia. 2009 May;23(5):961-70 PMID: 19151776
  8. Selective cyclin-dependent kinase 2/cyclin A antagonists that differ from ATP site inhibitors block tumor growth.
    Cancer Res. 2003 Mar 1;63(5):1020-4 PMID: 12615717
  9. Structure of the catalytic domain of human polo-like kinase 1.
    Biochemistry. 2007 May 22;46(20):5960-71 PMID: 17461553
  10. Cell cycle, CDKs and cancer: a changing paradigm.
    Nat Rev Cancer. 2009 Mar;9(3):153-66 PMID: 19238148
  11. Pyrazolo[1,5-a]-1,3,5-triazine as a purine bioisostere: access to potent cyclin-dependent kinase inhibitor (R)-roscovitine analogue.
    J Med Chem. 2009 Feb 12;52(3):655-63 PMID: 19128055
  12. Normal cells, but not cancer cells, survive severe Plk1 depletion.
    Mol Cell Biol. 2006 Mar;26(6):2093-108 PMID: 16507989
  13. A unique domain of pRb2/p130 acts as an inhibitor of Cdk2 kinase activity.
    J Biol Chem. 1997 Aug 22;272(34):20971-4 PMID: 9261093
  14. Cdk2 knockout mice are viable.
    Curr Biol. 2003 Oct 14;13(20):1775-85 PMID: 14561402
  15. Cyclin D-dependent kinases, INK4 inhibitors and cancer.
    Biochim Biophys Acta. 2002 Mar 14;1602(1):73-87 PMID: 11960696
  16. Reaching for high-hanging fruit in drug discovery at protein-protein interfaces.
    Nature. 2007 Dec 13;450(7172):1001-9 PMID: 18075579
  17. Differential inhibition of protein kinase C isozymes by UCN-01, a staurosporine analogue.
    Mol Pharmacol. 1994 Jun;45(6):1207-14 PMID: 8022414
  18. Modifications of the isonipecotic acid fragment of SNS-032: analogs with improved permeability and lower efflux ratio.
    Bioorg Med Chem Lett. 2008 Dec 1;18(23):6236-9 PMID: 18926699
  19. Toxicity and toxicokinetics of the cyclin-dependent kinase inhibitor AG-024322 in cynomolgus monkeys following intravenous infusion.
    Cancer Chemother Pharmacol. 2008 Nov;62(6):1091-101 PMID: 18509643
  20. Haploinsufficiency of the cdc2l gene contributes to skin cancer development in mice.
    Carcinogenesis. 2007 Sep;28(9):2028-35 PMID: 17389615
  21. AZD7762, a novel checkpoint kinase inhibitor, drives checkpoint abrogation and potentiates DNA-targeted therapies.
    Mol Cancer Ther. 2008 Sep;7(9):2955-66 PMID: 18790776
  22. Phase I study of flavopiridol in combination with Paclitaxel and Carboplatin in patients with non-small-cell lung cancer.
    Clin Lung Cancer. 2008 May;9(3):160-5 PMID: 18621626
  23. The RB and p53 pathways in cancer.
    Cancer Cell. 2002 Aug;2(2):103-12 PMID: 12204530
  24. A small-molecule inhibitor of Mps1 blocks the spindle-checkpoint response to a lack of tension on mitotic chromosomes.
    Curr Biol. 2005 Jun 7;15(11):1070-6 PMID: 15936280
  25. Potentiation of paclitaxel-induced apoptosis by the novel cyclin-dependent kinase inhibitor NU6140: a possible role for survivin down-regulation.
    Mol Cancer Ther. 2005 Sep;4(9):1328-37 PMID: 16170024
  26. The radiosensitizing agent 7-hydroxystaurosporine (UCN-01) inhibits the DNA damage checkpoint kinase hChk1.
    Cancer Res. 2000 Apr 15;60(8):2108-12 PMID: 10786669
  27. SU6668 is a potent antiangiogenic and antitumor agent that induces regression of established tumors.
    Cancer Res. 2000 Aug 1;60(15):4152-60 PMID: 10945623
  28. Identification and characterization of a novel and specific inhibitor of the ataxia-telangiectasia mutated kinase ATM.
    Cancer Res. 2004 Dec 15;64(24):9152-9 PMID: 15604286
  29. Cell cycle phenotype-based optimization of G2-abrogating peptides yields CBP501 with a unique mechanism of action at the G2 checkpoint.
    Mol Cancer Ther. 2007 Jan;6(1):147-53 PMID: 17237275
  30. A census of mitotic cancer genes: new insights into tumor cell biology and cancer therapy.
    Carcinogenesis. 2007 May;28(5):899-912 PMID: 17259655
  31. PHA-739358, a potent inhibitor of Aurora kinases with a selective target inhibition profile relevant to cancer.
    Mol Cancer Ther. 2007 Dec;6(12 Pt 1):3158-68 PMID: 18089710
  32. Germline mutations in the p16INK4a binding domain of CDK4 in familial melanoma.
    Nat Genet. 1996 Jan;12(1):97-9 PMID: 8528263
  33. Inducible pRb2/p130 expression and growth-suppressive mechanisms: evidence of a pRb2/p130, p27Kip1, and cyclin E negative feedback regulatory loop.
    Cancer Res. 2000 May 15;60(10):2737-44 PMID: 10825149
  34. Keeping checkpoint kinases in line: new selective inhibitors in clinical trials.
    Expert Opin Investig Drugs. 2008 Sep;17(9):1331-40 PMID: 18694366
  35. Enhancement of radiation response in p53-deficient cancer cells by the Aurora-B kinase inhibitor AZD1152.
    Oncogene. 2008 May 22;27(23):3244-55 PMID: 18084327
  36. A novel therapeutic combination using PD 0332991 and bortezomib: study in the 5T33MM myeloma model.
    Cancer Res. 2008 Jul 15;68(14):5519-23 PMID: 18632601
  37. Aurora kinases as anticancer drug targets.
    Clin Cancer Res. 2008 Mar 15;14(6):1639-48 PMID: 18347165
  38. Cellular effects of purvalanol A: a specific inhibitor of cyclin-dependent kinase activities.
    Int J Cancer. 2002 Feb 20;97(6):761-9 PMID: 11857351
  39. Fragment-based discovery of the pyrazol-4-yl urea (AT9283), a multitargeted kinase inhibitor with potent aurora kinase activity.
    J Med Chem. 2009 Jan 22;52(2):379-88 PMID: 19143567
  40. Mechanisms of mitotic cell death induced by chemotherapy-mediated G2 checkpoint abrogation.
    Cancer Res. 2007 Jan 1;67(1):339-45 PMID: 17210716
  41. On the road to cancer: aneuploidy and the mitotic checkpoint.
    Nat Rev Cancer. 2005 Oct;5(10):773-85 PMID: 16195750
  42. [The 2001 Nobel Prize in Physiology or Medicine].
    Tidsskr Nor Laegeforen. 2001 Dec 10;121(30):3500 PMID: 11808003
  43. REPLACE: a strategy for iterative design of cyclin-binding groove inhibitors.
    Chembiochem. 2006 Dec;7(12):1909-15 PMID: 17051658
  44. Cyclin-dependent kinase 5 activity controls cell motility and metastatic potential of prostate cancer cells.
    Cancer Res. 2006 Aug 1;66(15):7509-15 PMID: 16885348
  45. Role of the ABCG2 drug transporter in the resistance and oral bioavailability of a potent cyclin-dependent kinase/Aurora kinase inhibitor.
    Mol Cancer Ther. 2006 Oct;5(10):2459-67 PMID: 17041089
  46. Mutations in the Plk gene lead to instability of Plk protein in human tumour cell lines.
    Nat Cell Biol. 2000 Nov;2(11):852-4 PMID: 11056542
  47. Specific protection against breast cancers by cyclin D1 ablation.
    Nature. 2001 Jun 28;411(6841):1017-21 PMID: 11429595
  48. Lining the pockets of kinases and phosphatases.
    Curr Opin Struct Biol. 2006 Dec;16(6):693-701 PMID: 17084073
  49. p107 uses a p21CIP1-related domain to bind cyclin/cdk2 and regulate interactions with E2F.
    Genes Dev. 1995 Jul 15;9(14):1740-52 PMID: 7622038
  50. Polo-like kinases (Plks) and cancer.
    Oncogene. 2005 Jan 10;24(2):287-91 PMID: 15640844
  51. Lethality to human cancer cells through massive chromosome loss by inhibition of the mitotic checkpoint.
    Proc Natl Acad Sci U S A. 2004 Jun 8;101(23):8699-704 PMID: 15159543
  52. Mutations in the retinoblastoma-related gene RB2/p130 in lung tumors and suppression of tumor growth in vivo by retrovirus-mediated gene transfer.
    Cancer Res. 2000 Jan 15;60(2):372-82 PMID: 10667590
  53. RB and cell cycle progression.
    Oncogene. 2006 Aug 28;25(38):5220-7 PMID: 16936740
  54. Interaction between the Cdk2/cyclin A complex and a small molecule derived from the pRb2/p130 spacer domain: a theoretical model.
    Cell Cycle. 2007 Nov 1;6(21):2591-3 PMID: 17726381
  55. The small-molecule CDK inhibitor, SNS-032, enhances cellular radiosensitivity in quiescent and hypoxic non-small cell lung cancer cells.
    Lung Cancer. 2009 Oct;66(1):37-47 PMID: 19193471
  56. Identification of a Bis-guanylhydrazone [4,4'-Diacetyldiphenylurea-bis(guanylhydrazone); NSC 109555] as a novel chemotype for inhibition of Chk2 kinase.
    Mol Pharmacol. 2007 Oct;72(4):876-84 PMID: 17616632
  57. A small molecule based on the pRb2/p130 spacer domain leads to inhibition of cdk2 activity, cell cycle arrest and tumor growth reduction in vivo.
    Oncogene. 2007 Mar 22;26(13):1829-39 PMID: 17043661
  58. Mice thrive without Cdk4 and Cdk2.
    Mol Oncol. 2007 Jun;1(1):72-83 PMID: 19383288
  59. Cyclin-dependent kinase 2 is essential for meiosis but not for mitotic cell division in mice.
    Nat Genet. 2003 Sep;35(1):25-31 PMID: 12923533
  60. Cdk4 deficiency inhibits skin tumor development but does not affect normal keratinocyte proliferation.
    Am J Pathol. 2002 Aug;161(2):405-11 PMID: 12163365
  61. Characterization of CHEK2 mutations in prostate cancer.
    Hum Mutat. 2006 Aug;27(8):742-7 PMID: 16835864
  62. Effects of the aurora kinase inhibitors AZD1152-HQPA and ZM447439 on growth arrest and polyploidy in acute myeloid leukemia cell lines and primary blasts.
    Haematologica. 2008 May;93(5):662-9 PMID: 18367484
  63. A phase I trial of the selective oral cyclin-dependent kinase inhibitor seliciclib (CYC202; R-Roscovitine), administered twice daily for 7 days every 21 days.
    Br J Cancer. 2007 Jan 15;96(1):29-37 PMID: 17179992
  64. A diaminocyclohexyl analog of SNS-032 with improved permeability and bioavailability properties.
    Bioorg Med Chem Lett. 2008 Nov 1;18(21):5763-5 PMID: 18842409
  65. Inhibition of polo-like kinase 1 by blocking polo-box domain-dependent protein-protein interactions.
    Chem Biol. 2008 May;15(5):459-66 PMID: 18482698
  66. Differential roles of checkpoint kinase 1, checkpoint kinase 2, and mitogen-activated protein kinase-activated protein kinase 2 in mediating DNA damage-induced cell cycle arrest: implications for cancer therapy.
    Mol Cancer Ther. 2006 Aug;5(8):1935-43 PMID: 16928813
  67. CR8, a potent and selective, roscovitine-derived inhibitor of cyclin-dependent kinases.
    Oncogene. 2008 Oct 2;27(44):5797-807 PMID: 18574471
  68. Mechanisms of action of flavopiridol.
    Crit Rev Oncol Hematol. 2001 May;38(2):139-70 PMID: 11311660
  69. A nonsense mutation (E1978X) in the ATM gene is associated with breast cancer.
    Breast Cancer Res Treat. 2009 Nov;118(1):207-11 PMID: 18807267
  70. P-glycoprotein plays a role in the oral absorption of BMS-387032, a potent cyclin-dependent kinase 2 inhibitor, in rats.
    Cancer Chemother Pharmacol. 2005 Feb;55(2):110-6 PMID: 15338193
  71. AZ703, an imidazo[1,2-a]pyridine inhibitor of cyclin-dependent kinases 1 and 2, induces E2F-1-dependent apoptosis enhanced by depletion of cyclin-dependent kinase 9.
    Cancer Res. 2006 Jan 1;66(1):435-44 PMID: 16397259
  72. Retinoblastoma protein and anaphase-promoting complex physically interact and functionally cooperate during cell-cycle exit.
    Nat Cell Biol. 2007 Feb;9(2):225-32 PMID: 17187060
  73. Synthesis and biological evaluation of N-(7-indolyl)-3-pyridinesulfonamide derivatives as potent antitumor agents.
    Bioorg Med Chem Lett. 2002 Aug 19;12(16):2097-100 PMID: 12127512
  74. Activity of a novel Aurora kinase inhibitor against the T315I mutant form of BCR-ABL: in vitro and in vivo studies.
    Cancer Sci. 2008 Jun;99(6):1251-7 PMID: 18429956
  75. Role of the cyclin-dependent kinase 9-related pathway in mammalian gene expression and human diseases.
    Cell Cycle. 2008 Dec;7(23):3664-8 PMID: 19029809
  76. Lack of cyclin-dependent kinase 4 inhibits c-myc tumorigenic activities in epithelial tissues.
    Mol Cell Biol. 2004 Sep;24(17):7538-47 PMID: 15314163
  77. Chromosomal passengers: conducting cell division.
    Nat Rev Mol Cell Biol. 2007 Oct;8(10):798-812 PMID: 17848966
  78. Somatic mutations in the DNA damage-response genes ATR and CHK1 in sporadic stomach tumors with microsatellite instability.
    Cancer Res. 2001 Nov 1;61(21):7727-30 PMID: 11691784
  79. AZD1152, a novel and selective aurora B kinase inhibitor, induces growth arrest, apoptosis, and sensitization for tubulin depolymerizing agent or topoisomerase II inhibitor in human acute leukemia cells in vitro and in vivo.
    Blood. 2007 Sep 15;110(6):2034-40 PMID: 17495131
  80. The retinoblastoma family: twins or distant cousins?
    Genome Biol. 2002 Aug 28;3(9):reviews3012 PMID: 12225593
  81. Failure to proliferate and mitotic arrest of CDK11(p110/p58)-null mutant mice at the blastocyst stage of embryonic cell development.
    Mol Cell Biol. 2004 Apr;24(8):3188-97 PMID: 15060143
  82. A phase I pharmacokinetic study of HMN-214, a novel oral stilbene derivative with polo-like kinase-1-interacting properties, in patients with advanced solid tumors.
    Clin Cancer Res. 2006 Sep 1;12(17):5182-9 PMID: 16951237
  83. Pharmacological abrogation of S-phase checkpoint enhances the anti-tumor activity of gemcitabine in vivo.
    Cell Cycle. 2007 Jan 1;6(1):104-10 PMID: 17245119
  84. Discovery and exploitation of inhibitor-resistant aurora and polo kinase mutants for the analysis of mitotic networks.
    J Biol Chem. 2009 Jun 5;284(23):15880-93 PMID: 19359241
  85. Cdk4 is indispensable for postnatal proliferation of the anterior pituitary.
    J Biol Chem. 2004 Dec 3;279(49):51100-6 PMID: 15456744
  86. Polo and Aurora kinases: lessons derived from chemical biology.
    Curr Opin Cell Biol. 2008 Feb;20(1):77-84 PMID: 18249108
  87. The retinoblastoma protein and cell cycle control.
    Cell. 1995 May 5;81(3):323-30 PMID: 7736585
  88. Synthetic lethal screen identification of chemosensitizer loci in cancer cells.
    Nature. 2007 Apr 12;446(7137):815-9 PMID: 17429401
  89. Low rates of aneuploidy promote tumorigenesis while high rates of aneuploidy cause cell death and tumor suppression.
    Cell Oncol. 2008;30(5):453 PMID: 18791276
  90. Inhibition of ataxia telangiectasia mutated kinase activity enhances TRAIL-mediated apoptosis in human melanoma cells.
    Cancer Res. 2009 Apr 15;69(8):3510-9 PMID: 19351839
  91. A quantitative analysis of kinase inhibitor selectivity.
    Nat Biotechnol. 2008 Jan;26(1):127-32 PMID: 18183025
  92. p130/pRb2 has growth suppressive properties similar to yet distinctive from those of retinoblastoma family members pRb and p107.
    Cancer Res. 1994 Nov 1;54(21):5556-60 PMID: 7923196
  93. 1-Acyl-1H-[1,2,4]triazole-3,5-diamine analogues as novel and potent anticancer cyclin-dependent kinase inhibitors: synthesis and evaluation of biological activities.
    J Med Chem. 2005 Jun 30;48(13):4208-11 PMID: 15974571
  94. ATM and related protein kinases: safeguarding genome integrity.
    Nat Rev Cancer. 2003 Mar;3(3):155-68 PMID: 12612651
  95. Inhibition of CDK1 as a potential therapy for tumors over-expressing MYC.
    Nat Med. 2007 Jul;13(7):820-7 PMID: 17589519
  96. Discovery, synthesis, and in vivo activity of a new class of pyrazoloquinazolines as selective inhibitors of aurora B kinase.
    J Med Chem. 2007 May 3;50(9):2213-24 PMID: 17373783
  97. A novel orally active small molecule potently induces G1 arrest in primary myeloma cells and prevents tumor growth by specific inhibition of cyclin-dependent kinase 4/6.
    Cancer Res. 2006 Aug 1;66(15):7661-7 PMID: 16885367
  98. Proteomic characterization of the angiogenesis inhibitor SU6668 reveals multiple impacts on cellular kinase signaling.
    Cancer Res. 2005 Aug 1;65(15):6919-26 PMID: 16061676
  99. The oral multitarget tumour growth inhibitor, ZK 304709, inhibits growth of pancreatic neuroendocrine tumours in an orthotopic mouse model.
    Gut. 2009 Feb;58(2):261-70 PMID: 18829975
  100. HMN-176, an active metabolite of the synthetic antitumor agent HMN-214, restores chemosensitivity to multidrug-resistant cells by targeting the transcription factor NF-Y.
    Cancer Res. 2003 Oct 15;63(20):6942-7 PMID: 14583495
  101. In vitro and in vivo activity of R547: a potent and selective cyclin-dependent kinase inhibitor currently in phase I clinical trials.
    Mol Cancer Ther. 2006 Nov;5(11):2644-58 PMID: 17121911
  102. N-&-N, a new class of cell death-inducing kinase inhibitors derived from the purine roscovitine.
    Mol Cancer Ther. 2008 Sep;7(9):2713-24 PMID: 18790752
  103. Discovery and evaluation of dual CDK1 and CDK2 inhibitors.
    Cancer Res. 2006 Apr 15;66(8):4299-308 PMID: 16618755
  104. Tailoring to RB: tumour suppressor status and therapeutic response.
    Nat Rev Cancer. 2008 Sep;8(9):714-24 PMID: 19143056
  105. Tyrosine kinase inhibition of multiple angiogenic growth factor receptors improves survival in mice bearing colon cancer liver metastases by inhibition of endothelial cell survival mechanisms.
    Cancer Res. 2001 Feb 15;61(4):1464-8 PMID: 11245452
  106. The RB family of cell cycle regulatory factors.
    J Cell Biochem Suppl. 1998;30-31:30-6 PMID: 9893252
  107. Biochemical and cellular characterization of VRX0466617, a novel and selective inhibitor for the checkpoint kinase Chk2.
    Mol Cancer Ther. 2007 Mar;6(3):935-44 PMID: 17363488
  108. Cyclin D1-dependent kinase activity in murine development and mammary tumorigenesis.
    Cancer Cell. 2006 Jan;9(1):13-22 PMID: 16413468
  109. Aurora-A: the maker and breaker of spindle poles.
    J Cell Sci. 2007 Sep 1;120(Pt 17):2987-96 PMID: 17715155
  110. Selective small-molecule inhibitor reveals critical mitotic functions of human CDK1.
    Proc Natl Acad Sci U S A. 2006 Jul 11;103(28):10660-5 PMID: 16818887
  111. Binding of TPX2 to Aurora A alters substrate and inhibitor interactions.
    Biochemistry. 2007 Sep 11;46(36):10287-95 PMID: 17705509
  112. Ablation of the spindle assembly checkpoint by a compound targeting Mps1.
    EMBO Rep. 2005 Sep;6(9):866-72 PMID: 16113653
  113. Who is the boss in the retinoblastoma family? The point of view of Rb2/p130, the little brother.
    Cancer Res. 2001 Jun 15;61(12):4651-4 PMID: 11406530
  114. Biological characterization of AT7519, a small-molecule inhibitor of cyclin-dependent kinases, in human tumor cell lines.
    Mol Cancer Ther. 2009 Feb;8(2):324-32 PMID: 19174555
  115. Role of checkpoint kinase 1 in preventing premature mitosis in response to gemcitabine.
    Cancer Res. 2005 Aug 1;65(15):6835-42 PMID: 16061666
  116. Cyclin-dependent kinase pathways as targets for cancer treatment.
    J Clin Oncol. 2006 Apr 10;24(11):1770-83 PMID: 16603719
  117. Chk1 and Chk2 kinases in checkpoint control and cancer.
    Cancer Cell. 2003 May;3(5):421-9 PMID: 12781359
  118. Cdk11 is a RanGTP-dependent microtubule stabilization factor that regulates spindle assembly rate.
    J Cell Biol. 2008 Mar 10;180(5):867-75 PMID: 18316407
  119. The cellular phenotype of AZ703, a novel selective imidazo[1,2-a]pyridine cyclin-dependent kinase inhibitor.
    Mol Cancer Ther. 2006 Mar;5(3):655-64 PMID: 16546980
  120. Specific inhibition of cyclin-dependent kinase 4/6 by PD 0332991 and associated antitumor activity in human tumor xenografts.
    Mol Cancer Ther. 2004 Nov;3(11):1427-38 PMID: 15542782
  121. Molecular and pharmacodynamic characteristics of the novel multi-target tumor growth inhibitor ZK 304709.
    Biomed Pharmacother. 2006 Jul;60(6):269-72 PMID: 16887322
  122. Identification of an hexapeptide that binds to a surface pocket in cyclin A and inhibits the catalytic activity of the complex cyclin-dependent kinase 2-cyclin A.
    J Biol Chem. 2006 Nov 24;281(47):35942-53 PMID: 17001081
  123. 1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazoles: identification of a potent Aurora kinase inhibitor with a favorable antitumor kinase inhibition profile.
    J Med Chem. 2006 Nov 30;49(24):7247-51 PMID: 17125279
  124. The wages of CIN.
    J Cell Biol. 2008 Feb 25;180(4):661-3 PMID: 18283117
  125. Identification of a novel subgroup of melanomas with KIT/cyclin-dependent kinase-4 overexpression.
    Cancer Res. 2008 Jul 15;68(14):5743-52 PMID: 18632627
  126. Cyclin-dependent kinase 4 expression is essential for neu-induced breast tumorigenesis.
    Cancer Res. 2005 Nov 15;65(22):10174-8 PMID: 16288002
  127. Genetic rescue of Cdk4 null mice restores pancreatic beta-cell proliferation but not homeostatic cell number.
    Oncogene. 2003 Aug 14;22(34):5261-9 PMID: 12917627
  128. AZD1152, a selective inhibitor of Aurora B kinase, inhibits human tumor xenograft growth by inducing apoptosis.
    Clin Cancer Res. 2007 Jun 15;13(12):3682-8 PMID: 17575233
  129. Targeted disruption of CDK4 delays cell cycle entry with enhanced p27(Kip1) activity.
    Mol Cell Biol. 1999 Oct;19(10):7011-9 PMID: 10490638
  130. Purvalanol A induces apoptosis and downregulation of antiapoptotic proteins through abrogation of phosphorylation of JAK2/STAT3 and RNA polymerase II.
    Anticancer Drugs. 2008 Jul;19(6):565-72 PMID: 18525315
  131. Mammalian cells cycle without the D-type cyclin-dependent kinases Cdk4 and Cdk6.
    Cell. 2004 Aug 20;118(4):493-504 PMID: 15315761
  132. Retinoblastoma family proteins: insights gained through genetic manipulation of mice.
    Cell Mol Life Sci. 2006 Apr;63(7-8):767-80 PMID: 16465443
  133. Flavopiridol administered using a pharmacologically derived schedule is associated with marked clinical efficacy in refractory, genetically high-risk chronic lymphocytic leukemia.
    Blood. 2007 Jan 15;109(2):399-404 PMID: 17003373
  134. The in vitro and in vivo effects of JNJ-7706621: a dual inhibitor of cyclin-dependent kinases and aurora kinases.
    Cancer Res. 2005 Oct 1;65(19):9038-46 PMID: 16204078
  135. Molecular and structural basis of polo-like kinase 1 substrate recognition: Implications in centrosomal localization.
    Proc Natl Acad Sci U S A. 2007 Feb 27;104(9):3107-12 PMID: 17307877
  136. Ataxia-telangiectasia: from a rare disorder to a paradigm for cell signalling and cancer.
    Nat Rev Mol Cell Biol. 2008 Oct;9(10):759-69 PMID: 18813293
  137. Selective killing of transformed cells by cyclin/cyclin-dependent kinase 2 antagonists.
    Proc Natl Acad Sci U S A. 1999 Apr 13;96(8):4325-9 PMID: 10200261
  138. Phase I dose escalation and pharmacokinetic study of BI 2536, a novel Polo-like kinase 1 inhibitor, in patients with advanced solid tumors.
    J Clin Oncol. 2008 Dec 1;26(34):5511-7 PMID: 18955456
  139. Genes involved in DNA repair are mutational targets in endometrial cancers with microsatellite instability.
    Cancer Res. 2002 Jul 15;62(14):4095-9 PMID: 12124347
  140. Structure of a Survivin-Borealin-INCENP core complex reveals how chromosomal passengers travel together.
    Cell. 2007 Oct 19;131(2):271-85 PMID: 17956729
  141. In vitro antitumor properties of a novel cyclin-dependent kinase inhibitor, P276-00.
    Mol Cancer Ther. 2007 Mar;6(3):918-25 PMID: 17363486
  142. Cyclin B1 is an efficacy-predicting biomarker for Chk1 inhibitors.
    Biomarkers. 2008 Sep;13(6):579-96 PMID: 18671143
  143. A randomized phase II pharmacokinetic and pharmacodynamic study of indisulam as second-line therapy in patients with advanced non-small cell lung cancer.
    Clin Cancer Res. 2007 Mar 15;13(6):1816-22 PMID: 17363538
  144. Biochemical characterization of GSK1070916, a potent and selective inhibitor of Aurora B and Aurora C kinases with an extremely long residence time1.
    Biochem J. 2009 May 13;420(2):259-65 PMID: 19284385
  145. Small interfering RNA-mediated Polo-like kinase 1 depletion preferentially reduces the survival of p53-defective, oncogenic transformed cells and inhibits tumor growth in animals.
    Cancer Res. 2005 Apr 1;65(7):2698-704 PMID: 15805268
  146. Critical requirement for cell cycle inhibitors in sustaining nonproliferative states.
    J Cell Biol. 2007 Mar 12;176(6):807-18 PMID: 17353358
  147. Monoallelic BUB1B mutations and defective mitotic-spindle checkpoint in seven families with premature chromatid separation (PCS) syndrome.
    Am J Med Genet A. 2006 Feb 15;140(4):358-67 PMID: 16411201
  148. Loss of Cdk4 expression causes insulin-deficient diabetes and Cdk4 activation results in beta-islet cell hyperplasia.
    Nat Genet. 1999 May;22(1):44-52 PMID: 10319860
  149. The crystal structure of cyclin A.
    Structure. 1995 Nov 15;3(11):1235-47 PMID: 8591034
  150. The small-molecule inhibitor BI 2536 reveals novel insights into mitotic roles of polo-like kinase 1.
    Curr Biol. 2007 Feb 20;17(4):304-15 PMID: 17291761
  151. Discovery of a potent and selective inhibitor of cyclin-dependent kinase 4/6.
    J Med Chem. 2005 Apr 7;48(7):2388-406 PMID: 15801831
  152. BI 2536, a potent and selective inhibitor of polo-like kinase 1, inhibits tumor growth in vivo.
    Curr Biol. 2007 Feb 20;17(4):316-22 PMID: 17291758
  153. Development and biological evaluation of a novel aurora A kinase inhibitor.
    Chembiochem. 2009 Feb 13;10(3):464-78 PMID: 19199284
  154. Chk2-deficient mice exhibit radioresistance and defective p53-mediated transcription.
    EMBO J. 2002 Oct 1;21(19):5195-205 PMID: 12356735
  155. Microtubules as a target for anticancer drugs.
    Nat Rev Cancer. 2004 Apr;4(4):253-65 PMID: 15057285
  156. CDK11(p58) is required for the maintenance of sister chromatid cohesion.
    J Cell Sci. 2007 Jul 15;120(Pt 14):2424-34 PMID: 17606997
  157. Cdk1 is sufficient to drive the mammalian cell cycle.
    Nature. 2007 Aug 16;448(7155):811-5 PMID: 17700700
  158. p130 and p107 use a conserved domain to inhibit cellular cyclin-dependent kinase activity.
    Mol Cell Biol. 1997 Jul;17(7):3566-79 PMID: 9199292
  159. Molecular basis of drug resistance in aurora kinases.
    Chem Biol. 2008 Jun;15(6):552-62 PMID: 18559266
  160. Aurora A and B kinases as targets for cancer: will they be selective for tumors?
    Expert Rev Anticancer Ther. 2006 Jan;6(1):109-20 PMID: 16375648
  161. Loss of RB1 induces non-proliferative retinoma: increasing genomic instability correlates with progression to retinoblastoma.
    Hum Mol Genet. 2008 May 15;17(10):1363-72 PMID: 18211953
  162. In vitro and in vivo antitumor properties of the cyclin dependent kinase inhibitor CYC202 (R-roscovitine).
    Int J Cancer. 2002 Dec 10;102(5):463-8 PMID: 12432547
  163. Inhibition of drug-resistant mutants of ABL, KIT, and EGF receptor kinases.
    Proc Natl Acad Sci U S A. 2005 Aug 2;102(31):11011-6 PMID: 16046538
  164. Polo-like kinases: conservation and divergence in their functions and regulation.
    Nat Rev Mol Cell Biol. 2009 Apr;10(4):265-75 PMID: 19305416
  165. Terameprocol, a novel site-specific transcription inhibitor with anticancer activity.
    IDrugs. 2008 Mar;11(3):204-14 PMID: 18311658
  166. P276-00, a novel cyclin-dependent inhibitor induces G1-G2 arrest, shows antitumor activity on cisplatin-resistant cells and significant in vivo efficacy in tumor models.
    Mol Cancer Ther. 2007 Mar;6(3):926-34 PMID: 17363487
  167. In vitro biological activity of a novel small-molecule inhibitor of polo-like kinase 1.
    Mol Cancer Ther. 2007 Feb;6(2):450-9 PMID: 17267659
  168. Functional analysis of pRb2/p130 interaction with cyclins.
    Cancer Res. 1996 May 1;56(9):2003-8 PMID: 8616840
  169. Flavopiridol in the treatment of chronic lymphocytic leukemia.
    Curr Opin Oncol. 2007 Nov;19(6):573-8 PMID: 17906454
  170. Transient inhibition of ATM kinase is sufficient to enhance cellular sensitivity to ionizing radiation.
    Cancer Res. 2008 Sep 15;68(18):7466-74 PMID: 18794134
Article Info
Journal
Nature reviews. Drug discovery
Abbr.
Nat Rev Drug Discov
ISSN
1474-1784
DOI
10.1038/nrd2907
Email
[email protected]
Published
2009-07-00
Pages
547-66
Language
English
Region
England
NLM ID
101124171
Subset
IM
External Links
PubMed source DOI: 10.1038/nrd2907 View journal details
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: [email protected]

Copyright © 2026.Genelibs Jinan Honghui Biotechnology Co., Ltd. 鲁ICP备20007159号-2